InvestorsHub Logo
icon url

someconcerns

02/13/17 7:17 PM

#15596 RE: ahall #15595

Rather than my throwing numbers out there, why not look at some of the articles and blogposts Leny Hettmansperger has put out over on Seeking Alpha. The most recent one I have is: http://seekingalpha.com/instablog/44479986-leny-hettmansperger/4955333-inexpensive-stock-star-portfolio-plx-63c-mstx-13c-wstl-65c-amrs-45c-xtnt-35c-cbio-50c?app=1&uprof=44&isDirectRoadblock=false

This one covers several stocks but a number of his but others focus on just MSTX. The link to his list of blogposts: http://seekingalpha.com/author/leny-hettmansperger/instablogs

That said, I think he was propounding the thesis that the stock will rise to $.30 or so before the reverse split. I sure don't know what the ratio in the r/s will be, but it will have to be high enough to support uplisting the shares.

After the R/S, he was estimating the shares would grow sharply, once MSTX management is let go and the company is renamed Savara. They have two phase 2 studies ongoing on different drugs, a great relationship with the CF Foundation (which has provided non-dilutive funding) and a coorperative working relationship with the FDA.

I came into this as a long-time Savara shareholder (private as of now) with confidence in Savara management.